Cargando…
Neue S3-Leitlinie Prostatakarzinom 2021 (Version 6.2) – Was hat sich beim fortgeschrittenen Prostatakarzinom geändert?
There have been numerous new findings from clinical trials in recent years regarding the treatment of metastatic hormone-sensitive or castration-resistant prostate cancer. The newly approved treatment options make therapy planning and therapy sequencing more challenging. In addition, local therapy o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911494/ https://www.ncbi.nlm.nih.gov/pubmed/36066611 http://dx.doi.org/10.1007/s00120-022-01927-z |